Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective conscientiously but unsuccessfully to develop an one-time therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as being a combination treatment in the curing of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my past few shares. The first CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set away the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a highly marketing picture in the Uptick Newswire interview which I came away with an inadequate viewpoint of the company.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, yet the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this expertise as well as connected intellectual property from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 zillion) and the very first new drug application approval ($five million), and also royalty payments of 5 percent of net sales after commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has made this inauspicious acquisition into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many therapies and multiple indications, it has this individual remedy and a “broad pipeline of indications” as it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an energetic business with diverse interests albeit centered on leronlimab, several illness sorts, multiple publications in addition to multiple delivering presentations.

Might it all be smoke and mirrors? That’s a question I’ve been asking myself with the really start of the interest of mine in this business. Judging by the multiples of thousands of diverse responses on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this question.

CytoDyn is a traditional battleground, or perhaps some may say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *